Durham, NC, United States of America

Patrick Joseph Roberts

This inventor holds 25 USPTO granted patents and 26 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Anti-Cancer Treatments. Top assignees: G1 Therapeutics, Inc., Gi Therapeutics, Inc., Pharmacosmos Holding A/s. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Joseph Roberts. Retrieved from https://idiyas.com/inventor/patrick-joseph-roberts

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25 

% Patents Active = 92.0

 

 

Average Co-Inventor Count = 4.2

ph-index = 9

Forward Citations = 213(Granted Patents)


Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Immune Response
Chemotherapy
Topoisomerase Inhibitors
CDK4/6 Inhibitors
HSPC-Sparing Treatments
Anti-Neoplastic
Tumor Treatment
Cell Proliferation
Dosing Regimens
Tricyclic Lactams
Renal Tissue Protection
Ischemia
25 patents (USPTO):Explore Patents

Title: **Patrick Joseph Roberts: Innovating Cancer Treatment with Patented Technologies**

Introduction

Patrick Joseph Roberts, based in Durham, NC, is a distinguished inventor with an impressive portfolio of 23 patents. His work primarily focuses on innovations in the medical field, particularly pertaining to cancer treatment. Through his inventions, he aims to enhance the efficacy of chemotherapy while minimizing damage to healthy cells.

Latest Patents

Roberts recently developed several noteworthy patents, including:

1. **Transient protection of normal cells during chemotherapy** - This patent presents improved compounds, compositions, and methods designed to transiently protect healthy cells, specifically hematopoietic stem and progenitor cells (HSPCs) and renal cells, from the damaging effects associated with DNA-damaging chemotherapeutic agents. The invention highlights the use of selective, short-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors administered to patients undergoing chemotherapy for proliferative disorders.

2. **HSPC-sparing treatments for RB-positive abnormal cellular proliferation** - This innovation introduces advanced compounds and methods for treating RB-positive cancers while mitigating negative impacts on healthy cells, particularly HSPCs, seen with traditional treatment methods. The compounds act as selective and transiently-acting CDK 4/6 inhibitors, enhancing the treatment of specific RB-positive cancers.

Career Highlights

Throughout his career, Roberts has made significant strides in the biopharmaceutical industry. He has worked with respected companies such as G1 Therapeutics, Inc. and Gi Therapeutics, Inc., where he contributed to the development of groundbreaking therapies that hold promise for improving patient outcomes in cancer treatment.

Collaborations

Roberts has collaborated with eminent professionals in his field, including Jay Copeland Strum and John Emerson Bisi. Together, they have focused on advancing therapeutic technologies and addressing challenges in cancer treatment.

Conclusion

Patrick Joseph Roberts exemplifies the spirit of innovation through his dedicated work and numerous patents. His contributions to the field of cancer treatment reflect a commitment to improving patient care by leveraging scientific advancements. As he continues to develop novel solutions, Roberts remains a prominent figure in the realm of medical patents and therapeutics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…